Antiinflammatory potential of nano‐curcumin as an alternative therapeutic agent for the treatment of mild‐to‐moderate hospitalized COVID‐19 patients in a placebo‐controlled clinical trial

The present study conducted a placebo‐controlled clinical trial to evaluate the impact of nano‐curcumin on the inflammatory cytokines in mild‐to‐moderate hospitalized COVID‐19 patients. A total of 60 COVID‐19 patients were randomly divided into nano‐curcumin and control groups, and then they receive...

Full description

Saved in:
Bibliographic Details
Published in:Phytotherapy Research 2022-02, Vol.36 (2), p.1023-1031
Main Authors: Asadirad, Ali, Nashibi, Roohangiz, Khodadadi, Ali, Ghadiri, Ata A, Sadeghi, Mahvash, Aminian, Azam, Dehnavi, Sajad
Format: Article
Language:English
Subjects:
Anti-inflammatory agents
Anti-Inflammatory Agents - therapeutic use
Chemical compounds
Clinical trials
Complications
coronavirus disease‐2019
COVID-19
Curcumin
Curcumin - therapeutic use
cytokine storm
Cytokines
Gene expression
Humans
Inflammation
inflammatory cytokines
Interferon
Laboratories
Parameters
Patients
Pharmacology
Placebos
SARS-CoV-2
Serum levels
severe acute respiratory syndrome‐coronavirus‐2
Tumor necrosis factor
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The present study conducted a placebo‐controlled clinical trial to evaluate the impact of nano‐curcumin on the inflammatory cytokines in mild‐to‐moderate hospitalized COVID‐19 patients. A total of 60 COVID‐19 patients were randomly divided into nano‐curcumin and control groups, and then they received 240 mg/day nano‐curcumin for 7 days. The clinical manifestation and laboratory parameters in patients were recorded on days 0 and seven. Also, SYBR Green real‐time PCR and ELISA techniques were implicated in assessing the mRNA expression of IFN‐γ, IL‐1β, IL‐6, MCP‐1, and TNF‐α and the serum levels of IL‐1β, IL‐6, and TNF‐α inflammatory mediators, respectively. Although the clinical manifestations and laboratory parameters improved via the nano‐curcumin treatment, the mRNA expression of IFN‐γ (p = 0.006) and TNF‐α (p = 0.04) were significantly reduced. Besides, a considerable difference was observed between the nano‐curcumin and control groups in the expression of IFN‐γ (p = 0.001), IL‐1β (p = 0.0002), and IL‐6 (p = 0.008). In addition, there was a significant difference between the nano‐curcumin and control groups in the serum levels of IL‐1β (p = 0.042). The evidence demonstrated that nano‐curcumin could be implicated as a complementary medication to act as an antiinflammatory agent and inhibit inflammatory complications.
ISSN:0951-418X
1099-1573
DOI:10.1002/ptr.7375